The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 1: 78 - 83

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.01.013

Clinical Research

Correlation of serum ferritin and 25⁃hydroxyvitamin D with cervical vascular plaque and cardiac metabolism index in elderly patients with nonalcoholic fatty liver disease

  • Lei LEI ,
  • Yun HU ,
  • Di ZHANG ,
  • Xinyu HUANG ,
  • Yu PENG
Expand
  • Department of Gastroenterology，Sichuan Academy of Medical Sciences-Sichuan Provincial People's Hospital，Chengdu 610072，Sichuan，China

Received date: 2024-07-23

  Online published: 2025-01-14

Fold

Abstract

Objective To investigate the correlation between serum ferritin （SF） and 25-hydroxyvitamin D ［25-（OH）D］ and cervical vascular plaque and cardiac metabolism index （CMI） in elderly patients with nonalcoholic fatty liver disease （NAFLD）. Methods 128 elderly patients with NAFLD in the hospital were selected as study group， and 80 healthy subjects with physical examination were included in control group. The levels of SF and 25-（OH）D were compared between study group and control group and among patients with different lesion degrees. According to the presence or absence of formation of carotid artery plaque， the patients were classified into plaque group （n = 36） and non-plaque group （n = 92）， and the clinical data， SF， 25-（OH）D and CMI were compared. The multiple factors affecting the cervical vascular plaque formation in elderly patients with NAFLD and the correlation of SF and 25-（OH）D levels with cervical vascular plaque and CMI were analyzed. Results Serum SF in study group was significantly higher than that in control group （P < 0.05） while 25-（OH）D level was significantly lower than that in control group （P < 0.05）. SF level was manifested as fatty liver group < steatohepatitis group < liver cirrhosis group （P < 0.05） while 25-（OH）D level revealed fatty liver group > steatohepatitis group > liver cirrhosis group （P < 0.05）. The BMI， diabetes mellitus， hyperlipidemia， serum ALT， AST， LDL-C， SF， FPG， FINS， HOMA-IR， CMI and NFS in plaque group were significantly higher than those in non-plaque group （P < 0.05） while serum 25-（OH）D level was significantly lower than that in non-plaque group （P < 0.05）. Multivariate Logistic regression analysis showed that increased BMI， serum LDL-C， SF， CMI and NFS were risk factors for carotid artery plaque formation in elderly patients with NAFLD （P < 0.05）， and serum 25-（OH）D level was a protective factor （P < 0.05）. Correlation analysis showed that SF was positively correlated with carotid artery plaque and CMI in NAFLD patients （P < 0.05）， and serum 25-（OH）D level was negatively correlated with carotid artery plaque and CMI （P < 0.05）. Conclusion Serum SF and 25-（OH）D are related to the progression of NAFLD， and may affect the cervical vascular plaque formation and cardiac metabolism. Serum SF and 25-（OH）D can be used as observation indicators for the diagnosis and treatment of vascular lesions in patients with NAFLD.

Key words： ferritin; 25-hydroxyvitamin D; nonalcoholic fatty liver disease; cervical vascular plaque; cardiac metabolism index; correlation

Cite this article

Lei LEI , Yun HU , Di ZHANG , Xinyu HUANG , Yu PENG . Correlation of serum ferritin and 25⁃hydroxyvitamin D with cervical vascular plaque and cardiac metabolism index in elderly patients with nonalcoholic fatty liver disease[J]. The Journal of Practical Medicine, 2025 , 41(1) : 78 -83 . DOI: 10.3969/j.issn.1006-5725.2025.01.013

References

1 TINCOPA M A， LOOMBA R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis［J］. Lancet Gastroenterol Hepatol， 2023， 8（7）： 660-670. doi:10.1016/s2468-1253(23)00066-3
2 GRANDER C， GRABHERR F， TILG H. Non-alcoholic fatty liver disease： Pathophysiological concepts and treatment options［J］. Cardiovasc Res， 2023， 119（9）： 1787-1798. doi:10.1093/cvr/cvad095
3 HUANG S C， LIU C J. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease： Challenges and perspectives［J］. Clin Mol Hepatol， 2023， 29（2）： 320-331. doi:10.3350/cmh.2022.0422
4 WANG X， ZHANG R， MAN S， et al. Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis［J］. Liver Int， 2023， 43（8）： 1691-1698. doi:10.1111/liv.15591
5 YAN J， GUAN T， GUO M， et al. Serum Ferritin and Non-alcoholic Fatty Liver Disease： A Meta-analysis and Systematic Review［J］. Turk J Gastroenterol， 2023， 34（9）： 952-960. doi:10.5152/tjg.2023.22453
6 KIM Y， CHANG Y， RYU S， et al. Resolution of， and Risk of Incident Non-alcoholic Fatty Liver Disease With Changes in Serum 25-hydroxy Vitamin D Status［J］. J Clin Endocrinol Metab， 2022， 107（8）： 3437-3447. doi:10.1210/clinem/dgac255
7 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南（2010年修订版）［J］. 中华肝脏病杂志，2010，18（3）：163-166.
8 国家卫生计生委脑卒中防治工程委员会. 中国脑卒中血管超声检查指导规范［J］. 中华医学超声杂志（电子版），2015，12（8）：599-610.
9 中华医学会肝病学分会，中华医学会消化病学分会，中华医学会感染病学分会. 肝纤维化诊断及治疗共识（2019年）［J］. 中华肝脏病杂志，2019，27（9）：657-667.
10 CIARDULLO S， MURACA E， CANNISTRACI R， et al. Low 25 （OH） vitamin D levels are associated with increased prevalence of nonalcoholic fatty liver disease and significant liver fibrosis［J］. Diabetes Metab Res Rev， 2023， 39（5）： 3628. doi:10.1002/dmrr.3628
11 GENUA I， IRUZUBIETA P， RODRIGUEZ-DUQUE J C， et al. NAFLD and type 2 diabetes： A practical guide for the joint management［J］. Gastroenterol Hepatol， 2023， 46（10）： 815-825. doi:10.1016/j.gastrohep.2022.12.002
12 TRASOLINI R， COX B， GALTS C， et al. Elevated serum ferritin in non-alcoholic fatty liver disease is not predictive of fibrosis［J］. Can Liver J， 2022， 5（2）： 152-159. doi:10.3138/canlivj-2021-0002
13 YAN J X， PAN B J， ZHAO P P， et al. Serum ferritin is correlated with non-alcoholic fatty liver disease in middle-aged and older patients with type 2 diabetes［J］. Endocr Connect， 2021， 10（12）： 1560-1569. doi:10.1530/ec-21-0367
14 YAN J， GUAN T， GUO M， et al. Serum Ferritin and Non-alcoholic Fatty Liver Disease： A Meta-analysis and Systematic Review［J］. Turk J Gastroenterol， 2023， 34（9）： 952-960. doi:10.5152/tjg.2023.22453
15 ARMANDI A， SANAVIA T， YOUNES R， et al. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease［J］. Gut， 2024， 73（5）： 825-834. doi:10.1136/gutjnl-2023-330815
16 马言， 田高鹏， 石兴文， 等. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性［J］. 中国临床药理学与治疗学， 2023， 28（9）： 1018-1026.
17 姚仁玲，朱艺璇，黄睿，等. 维生素摄入量与代谢相关脂肪性肝病进程的相关性分析［J］. 实用医学杂志，2024，40（6）：820-826.
18 IBRAHIM M N， KHALIFA A A， HEMEAD D A， et al. 1，25-Dihydroxycholecalciferol down-regulates 3-mercaptopyruvate sulfur transferase and caspase-3 in rat model of non-alcoholic fatty liver disease［J］. J Mol Histol， 2023， 54（2）： 119-134. doi:10.1007/s10735-023-10118-9
19 SHENG Q， SHI H， LIU S， et al. Serum 25-hydroxyvitamin D levels and the risk of non-alcoholic fatty liver： A two-sample Mendelian randomization study［J］. Saudi J Gastroenterol， 2023， 29（1）： 39-46. doi:10.4103/sjg.sjg_297_22
20 QU Y L， SONG Y H， SUN R R， et al. Serum Vitamin D Level in Overweight Individuals and Its Correlation With the Incidence of Non-alcoholic Fatty Liver Disease［J］. Physiol Res， 2024， 73（2）： 265-271.
21 CAI J， ZHANG Z， LIU J， et al. Correlation between serum 25-OH vitamin D expression and non-alcoholic fatty liver disease［J］. Exp Ther Med， 2020， 19（3）： 1681-1686.
22 HANG X， YU X， FAN S. Lower extremity arterial plaque in patients with type 2 diabetes mellitus： A cross-sectional study of 25-（OH）D3 and other risk factors［J］. J Diabetes Complications， 2024， 38（1）： 108665. doi:10.1016/j.jdiacomp.2023.108665
23 YANG N， LU Y， CAO L， et al. The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults［J］. J Clin Lab Anal， 2022， 36（2）： 24225. doi:10.1002/jcla.24225
24 ZOU J， XIONG H， ZHANG H， et al. Association between the cardiometabolic index and non-alcoholic fatty liver disease： Insights from a general population［J］. BMC Gastroenterol， 2022， 22（1）： 20. doi:10.1186/s12876-022-02099-y
25 LUM J H M， CHEAH M C C， LEOW W Q， et al. Clinical profile of non-alcoholic fatty liver disease in nonobese patients［J］. J Gastroenterol Hepatol， 2021， 36（1）： 257-261. doi:10.1111/jgh.15154
26 CHO Y， PARK H S， HUH B W， et al. Non-Alcoholic Fatty Liver Disease with Sarcopenia and Carotid Plaque Progression Risk in Patients with Type 2 Diabetes Mellitus［J］. Diabetes Metab J， 2023， 47（2）： 232-241. doi:10.4093/dmj.2021.0355
27 SAGAR A， L R， FARHEEN S A. A Study of Correlation between Non Alcoholic Fatty Liver Disease and Carotid Atherosclerosis［J］. J Assoc Physicians India， 2022， 70（4）：11-12.
Options
Outlines

/

〈 〉